KYMR241220P40000
- 0.00
- 0.000.00%
Kymera Therapeutics Newsroom
Stephens Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $65
Kymera Therapeutics Price Target Announced at $65.00/Share by Stephens & Co.
Kymera Therapeutics Analyst Ratings
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $49
Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $53
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)
UBS Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $74
Kymera Therapeutics Is Maintained at Buy by UBS
Kymera Therapeutics Analyst Ratings
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56
Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $52
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $53 to $60
Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating
Leerink Partners Maintains Kymera Therapeutics(KYMR.US) With Buy Rating
Leerink Partners Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
Kymera Therapeutics Analyst Ratings
Oppenheimer Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)